Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now
Promosome v. Moderna | Patent Lawsuit 3:23-cv-01047

Promosome, LLC v. Moderna, Inc.

3:23-cv-01047 S.D. Cal. Closed US8853179B2
Get a prior-art report

Infringement action filed 6 Jun 2023 in the United States District Court for the Southern District of California and closed 30 Oct 2023, with US8853179B2 asserted. Recorded basis of termination: dismissed without prejudice.

Case recordPatsnap Litigation Data·

Case record

Patent involved
US8853179B2
Application no.
US13/203229
Case no.
3:23-cv-01047
Verdict cause
Infringement action
Court
S.D. Cal.
Court level
District Court
Case region
California
Chief judge
None recorded
Trial level
First instance
Filed – Closed
6 Jun 2023 – 30 Oct 2023
Duration
146 days
Basis of termination
Dismissed without Prejudice
Products & marks
Spikevax®
Validity challenges
None recorded
Source: Patsnap Litigation Data. Case 3:23-cv-01047, United States District Court for the Southern District of California. Open this record in Eureka
Patsnap Eureka

Check this patent against your own product

Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.

Get an FTO claim chart
10,000 free credits to start
Patent at issue
US8853179B2 Active App. US13/203229

Reengineering mRNA primary structure for enhanced protein production

Described herein are rules to modify natural mRNAs or to engineer synthetic mRNAs to increase their translation efficiencies. These rules describe modifications to mRNA coding and 3′ UTR sequences intended to enhance protein synthesis by: 1) decreasing ribosomal diversion via AUG or non-canonical initiation codons in coding sequences, and/or 2) by evading miRNA-mediated down-regulation by eliminating one or more miRNA binding sites in coding sequences.

Read claims and description in Eureka
Patent standing
Legal status
Active
Granted
7 Oct 2014
Earliest priority
24 Feb 2009
Est. expiry
28 May 2030
Validity challenges
None recorded
Licences recorded
None recorded
Classification
C12N15/11C12P21/02
Prosecution counsel
COOLEY LLP
Examiner
WHITEMAN, BRIAN
US8853179B2 patent drawing, figure 1
Fig. 1
US8853179B2 patent drawing, figure 2
Fig. 2
Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document. Break down the claims
Parties & counsel

Parties of record

Defendant

Moderna, Inc.

Core tech
Not recorded
Counsel
Gregory Bombard · Joseph Thomas Ergastolo · Megan Alexandra Chacon · Scott Joseph Bornstein
Firm
Fish & Richardson PC, Greenberg Traurig LLP, Greenberg Traurig PA, Wright, L’Estrange & Ergastolo LLP

Counsel of record

Source: case record + Patsnap company data. Attorney names appear as recorded in the docket. Compare both portfolios
Outcome

Basis of termination

From the record · verbatim

“Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), Plaintiff Promosome LLC hereby dismisses, without prejudice, this action against all Defendants in its entirety and provides notice of the same. For avoidance of doubt, Defendants Moderna, Inc., Moderna US, Inc., and ModernaTX, Inc. have not served an answer or motion for summary judgment in this action. Accordingly, Plaintiff hereby notices voluntary dismissal of this action in its entirety, without prejudice. See Fed. R. Civ. P. (a)(1)(B).”

Case 3:23-cv-01047 · S.D. Cal. · closed 30 October 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.

Related cases

Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.

FAQ

Frequently asked questions

What is case 3:23-cv-01047?

3:23-cv-01047 is a patent infringement action brought by Promosome, LLC against Moderna, Inc., filed on 6 Jun 2023 in the United States District Court for the Southern District of California. The case closed on 30 October 2023.

Which patent was asserted in 3:23-cv-01047?

US8853179B2 (“Reengineering mRNA primary structure for enhanced protein production”), assigned to THE SCRIPPS RESEARCH INSTITUTE, currently active. The record also lists Spikevax®.

How was case 3:23-cv-01047 terminated?

The recorded basis of termination is dismissed without prejudice. The termination text reads: “Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), Plaintiff Promosome LLC hereby dismisses, without prejudice, this action against all Defendants in its entirety and provides notice of the same. For avoidance of doubt, Defendants Moderna, Inc., Moderna US, Inc., and ModernaTX, Inc. have not served an answer or motion for summary judgment in this action. Accordingly, Plaintiff hereby notices voluntary dismissal of this action in its entirety, without prejudice. See Fed. R. Civ. P. (a)(1)(B).”

What does dismissal without prejudice mean?

A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.

How long did case 3:23-cv-01047 take?

146 calendar days, from filing on 6 Jun 2023 to closure on 30 October 2023.

Who were the attorneys and the judge in 3:23-cv-01047?

Amanda Bonn, Joseph Samuel Grinstein and Taylor Hoogendoorn are recorded as counsel for plaintiff Promosome. Gregory Bombard, Joseph Thomas Ergastolo, Megan Alexandra Chacon and Scott Joseph Bornstein appear for defendant Moderna.

Answers reproduce fields from the case record for 3:23-cv-01047 and do not constitute legal advice. Ask your own question

Disclaimer. This page reproduces publicly available court docket data for case 3:23-cv-01047 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.

Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.

No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

Related Litigation Cases

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.